What Is Vasoactive Intestinal Peptide?
Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide involved in receptor signaling across the nervous, gastrointestinal, cardiovascular and immune systems.
Its human peptide sequence is:
HSDAVFTDNYTRLRKQMAVKKYLNSILN
SUNONE supplies research-grade VIP, CAS 37221-79-7, for qualified laboratory, analytical and manufacturing research.
SUNONE VIP Product Page:
VIP and PACAP Are Related—but Not Identical
VIP is frequently discussed together with PACAP, or pituitary adenylate cyclase-activating polypeptide.
This is understandable because both peptides belong to the same broader peptide family and share substantial sequence similarity.
They also activate overlapping receptors.
However:
shared receptor activity does not mean identical receptor pharmacology.
That distinction is important when interpreting VIP research.
Which Receptors Does VIP Activate?
The main receptor system includes:
VPAC1
VPAC2
PAC1
VIP and PACAP both bind with high affinity to VPAC1 and VPAC2.
The key difference is PAC1.
PAC1 is much more selective for PACAP, while VIP has far lower affinity for this receptor.
A useful research framework is:
VIP → VPAC1 + VPAC2
while
PACAP → VPAC1 + VPAC2 + strong PAC1 activity
This is one reason evidence generated with PACAP should not automatically be assigned to VIP.
Why Does Receptor Selectivity Matter?
Receptor identity can influence downstream signaling and experimental interpretation.
VPAC1 and VPAC2 are class B GPCRs that commonly signal through pathways involving:
- adenylate cyclase;
- cAMP;
- protein kinase signaling;
- calcium-related signaling;
- downstream cellular responses.
PAC1 can activate overlapping pathways but has its own ligand selectivity and signaling characteristics.
Therefore, two related peptides can share part of a signaling system while still producing different experimental profiles.
Why “VIP/PACAP Peptide” Can Be an Oversimplification
Some online articles describe VIP and PACAP almost as interchangeable molecules.
That can create an evidence-transfer problem.
If a study uses PACAP and produces a strong PAC1-dependent result, that result should not automatically be described as evidence for VIP.
Likewise, a VPAC1- or VPAC2-mediated VIP experiment does not necessarily describe PAC1 biology.
For researchers:
peptide identity → receptor selectivity → signaling pathway → biological interpretation.
This order matters.
What Areas of VIP Research Are Common?
Published research has investigated VIP in areas including:
- neuropeptide signaling;
- vasodilation;
- gastrointestinal physiology;
- immune signaling;
- smooth-muscle biology;
- circadian and CNS pathways;
- receptor pharmacology.
Because VPAC receptors are widely distributed across tissues, VIP biology is broad.
That does not mean every biological observation has been demonstrated as a clinical benefit.
Mechanistic and preclinical evidence should be interpreted separately from therapeutic claims.
What Do VIP Reviews Say?
Current online VIP reviews are mixed.
Positive anecdotal comments sometimes mention:
- improved perceived energy;
- improved mental clarity;
- improved general well-being;
- improved daily functioning;
- improved perceived resilience.
Negative or neutral reports include:
- fatigue;
- sleepiness;
- anxiety;
- bloating;
- flu-like sensations;
- feeling generally unwell;
- little or no noticeable benefit.
Many online reports involve specific compounded preparations, nasal products or disease-specific protocols.
This introduces major confounding variables.
Therefore:
VIP reviews are anecdotal search sentiment—not controlled scientific evidence.
Why VIP Reviews Should Not Be Treated as Aviptadil Evidence
VIP is also associated with the name Aviptadil.
However, research-grade VIP material and regulated or investigational pharmaceutical formulations should not automatically be considered equivalent.
Differences may include:
- formulation;
- excipients;
- purity profile;
- manufacturing controls;
- route-specific characteristics;
- pharmaceutical quality standards.
Human pharmaceutical data cannot automatically establish the safety or efficacy of a research-grade peptide material.
Why Molecular Identity Matters for VIP Research
VIP is a 28-amino-acid peptide, and correct sequence identity is essential.
When evaluating research-grade VIP, laboratories may need to consider:
- peptide sequence;
- molecular mass;
- HPLC purity;
- related peptide impurities;
- degradation;
- batch consistency;
- applicable analytical documentation.
A simple product label such as “VIP peptide” does not fully describe material quality.
What Should Researchers Check When Choosing a VIP Supplier?
When evaluating a research-grade VIP supplier, laboratories should prioritize batch-level analytical documentation.
SUNONE currently lists:
Product: Vasoactive Intestinal Peptide
Synonyms: VIP, Vasoactive Intestinal Polypeptide, Aviptadil
CAS: 37221-79-7
Formula: C147H237N43O43S
Molecular Weight: 3326.8 g/mol
Sequence Length: 28 amino acids
Purity: ≥99% HPLC
Form: Lyophilized
Grade: Research Grade
Storage: 2–8°C, protect from light
Batch-specific COA, HPLC and applicable analytical documentation should be reviewed before experimental use.
Final Thoughts
A common search question is:
“Are VIP and PACAP the same?”
The research answer is no.
They share VPAC receptor biology, but their receptor profiles are not identical.
A stronger scientific framework is:
VIP identity → VPAC1 / VPAC2 → receptor signaling → biological interpretation
versus
PACAP identity → VPAC1 / VPAC2 / PAC1 → different receptor balance.
For laboratories comparing a Vasoactive Intestinal Peptide supplier, correct molecular identity, sequence confirmation, HPLC purity and batch-specific analytical documentation should take priority over broad neurological, immune or wellness claims.
SUNONE research peptide is for qualified labrtorynt, diagnois, druc tor mmatct or veteimant, use.research only, Not for human consumption, clinical treame.
Leave a Reply